Skip to main content
ANAB
NASDAQ Life Sciences

AnaptysBio 在德拉瓦州法院获得针对 GSK 案件的驳回决定

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
7
Price
$59.85
Mkt Cap
$1.693B
52W Low
$11.402
52W High
$60.6
Market data snapshot near publication time

summarizeSummary

德拉瓦州衡平法院批准了 AnaptysBio 提出的驳回动议，解决了公司涉及 GSK 的法律事务，有利于公司。该积极的法律结果是在 4 月 24 日做出的类似决定之后，该法院驳回了 Tesaro 对 AnaptysBio 提出的预期违约诉讼。德拉瓦州衡平法院中反复的成功表明 AnaptysBio 拥有强大的法律地位，并消除了潜在的法律不确定性，这对公司来说是一个重要的积极因素。投资者将关注被驳回的诉讼的具体性质和任何剩余的诉讼细节。

在该公告发布时，ANAB的交易价格为$59.85，交易所为NASDAQ，所属行业为Life Sciences，市值约为$16.9亿。 52周交易区间为$11.40至$60.60。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed ANAB - Latest Insights

ANAB
Apr 27, 2026, 2:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
AnaptysBio Secures Delaware Court Dismissal in GSK Case
Sentiment: Positive
View Wiseek Article
ANAB
Apr 24, 2026, 4:17 PM EDT
Filing Type: 8-K/A
Importance Score:
8
AnaptysBio Files Pro Forma Financials Post-Spin-Off of First Tracks Biotherapeutics
Sentiment: Neutral
View Wiseek Article
ANAB
Apr 24, 2026, 3:41 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Delaware Court Dismisses Tesaro Breach Claim Against AnaptysBio
Sentiment: Positive
View Wiseek Article
ANAB
Apr 20, 2026, 5:33 PM EDT
Source: Wiseek News
Importance Score:
8
AnaptysBio Completes Spin-Off, Transfers $100M to First Tracks in Separation Deal
Sentiment: Positive
View Wiseek Article
ANAB
Apr 20, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
9
AnaptysBio Completes Spin-Off of First Tracks Biotherapeutics, Retains $140M+ Cash, and Transitions to Royalty Management Model
Sentiment: Positive
View Wiseek Article
ANAB
Apr 20, 2026, 1:15 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
AnaptysBio Soars to 52-Week High Post-Spinoff; First Tracks Biotherapeutics Shares Decline
Sentiment: Positive
View Wiseek Article
ANAB
Mar 27, 2026, 9:19 AM EDT
Filing Type: 8-K
Importance Score:
9
AnaptysBio Approves Spin-Off of First Tracks Biotherapeutics, Authorizes $100M Buyback, and Appoints Key Director
Sentiment: Positive
View Wiseek Article
ANAB
Mar 27, 2026, 9:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
$145M Private Placement Secured for AnaptysBio's Spin-Off, First Tracks Biotherapeutics
Sentiment: Positive
View Wiseek Article
ANAB
Mar 03, 2026, 4:15 PM EST
Source: Reuters
Importance Score:
7
AnaptysBio Posts $49.6 Million Net Income in Q4
Sentiment: Neutral
View Wiseek Article
ANAB
Mar 03, 2026, 4:15 PM EST
Source: GlobeNewswire
Importance Score:
9
AnaptysBio to Spin Off Biopharma Unit as First Tracks Biotherapeutics in Q2 2026 to Unlock Value
Sentiment: Positive
View Wiseek Article